sotalol has been researched along with Torsade de Pointes in 114 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 8.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "We present a case of sotalol-induced prolongation of the QT-interval with torsades de pointes in an octogenarian who was hospitalized because of gastroenteritis causing prerenal acute renal failure." | 7.75 | Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes. ( Michiels, V; Miljoen, H; Vrints, C, 2009) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 7.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "To evaluate the effects of W-7, a calmodulin inhibitor, on transmural dispersion of repolarization (TDR), early after depolarization (EAD) and torsade de pointes (TdP) induction after administration of d-sotalol in isolated rabbit heart." | 7.73 | [Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model]. ( Bai, R; Li, Y; Liu, N; Pu, J; Wang, L; Zhang, CT, 2005) |
| "We present 4 patients with atrial fibrillation treated with sotalol who developed torsade de pointes due to marked prolongation of the QT interval." | 7.72 | A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist. ( Chua, T; Hsu, LF; Kam, RM; Tan, HH; Teo, WS, 2003) |
| "Proarrhythmia in the form of Torsade de Pointes tachycardia (TdP) is a well-known complication of sotalol treatment." | 7.69 | [Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels]. ( Appel, JM; Sigurd, B, 1996) |
| "Torsade de pointes is a well-established toxic effect of sotalol hydrochloride." | 7.69 | Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. ( Estes, NA; Foote, CB; Homoud, MK; Link, MS; Sloan, SB; Wang, PJ, 1997) |
| "The present study was undertaken to test the hypothesis that women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to the QT-prolonging antiarrhythmic drug d,l-sotalol." | 7.69 | Sex difference in risk of torsade de pointes with d,l-sotalol. ( Archibald, D; Hardy, S; Lehmann, MH; MacNeil, DJ; quart, B, 1996) |
| " The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration." | 7.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Torsade de pointes is a polymorphic ventricular tachyarrhythmia associated with a long QT interval." | 6.40 | Torsade de pointes with sotalol overdose treated successfully with lidocaine. ( Assimes, TL; Malcolm, I, 1998) |
| "Heart failure was induced in 35 female rabbits by rapid ventricular pacing, resulting in a significant decrease of ejection fraction." | 5.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 5.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1." | 5.31 | Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "Sotalol has been commonly used in cases of angina pectoris and hypertension." | 5.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| "The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) of < or = 40%." | 5.08 | Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? ( Camm, AJ; Cooper, W; Friedman, PL; MacNeil, DJ; Moulton, KM; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1998) |
| " Sotalol, dofetilide, and ibutilide may induce torsade de pointes in 2-8% of patients, whereas amiodarone induces torsade de pointes in less than 1%." | 4.84 | Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. ( Kluger, J; Shah, SA; White, CM, 2007) |
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 4.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| "Sotalol, a Vaughan-Williams Class III antiarrhythmic medication, is used to manage atrial arrhythmias." | 3.96 | Multicenter Analysis of Dosing Protocols for Sotalol Initiation. ( Biswas, M; Chung, M; Levy, A; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2020) |
| "We present a case of significant QTc prolongation with torsade de pointes in a female patient with a DDD pacemaker, who had been treated with an established dose of sotalol for two years." | 3.77 | Late proarrhythmia on sotalol therapy triggered by emotional stress. ( Grajek, S; Ochotny, R; Straburzyńska-Migaj, E; Wachowiak-Baszyńska, H, 2011) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "We present a case of sotalol-induced prolongation of the QT-interval with torsades de pointes in an octogenarian who was hospitalized because of gastroenteritis causing prerenal acute renal failure." | 3.75 | Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes. ( Michiels, V; Miljoen, H; Vrints, C, 2009) |
| "To evaluate the effects of W-7, a calmodulin inhibitor, on transmural dispersion of repolarization (TDR), early after depolarization (EAD) and torsade de pointes (TdP) induction after administration of d-sotalol in isolated rabbit heart." | 3.73 | [Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model]. ( Bai, R; Li, Y; Liu, N; Pu, J; Wang, L; Zhang, CT, 2005) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 3.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "We present 4 patients with atrial fibrillation treated with sotalol who developed torsade de pointes due to marked prolongation of the QT interval." | 3.72 | A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist. ( Chua, T; Hsu, LF; Kam, RM; Tan, HH; Teo, WS, 2003) |
| "This study examines the effects of nicorandil, a K(+) channel opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)." | 3.70 | Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. ( Antzelevitch, C; Shimizu, W, 2000) |
| " Spontaneous and stimulation-induced polymorphic ventricular tachycardia with characteristics of torsade de pointes (TdP) developed in the presence of dl-sotalol." | 3.70 | Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. ( Antzelevitch, C; Yan, GX, 1998) |
| "The present study was undertaken to test the hypothesis that women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to the QT-prolonging antiarrhythmic drug d,l-sotalol." | 3.69 | Sex difference in risk of torsade de pointes with d,l-sotalol. ( Archibald, D; Hardy, S; Lehmann, MH; MacNeil, DJ; quart, B, 1996) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "Torsade de pointes is a well-established toxic effect of sotalol hydrochloride." | 3.69 | Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. ( Estes, NA; Foote, CB; Homoud, MK; Link, MS; Sloan, SB; Wang, PJ, 1997) |
| "The aim of this study was to assess the antiarrhythmic efficacy and safety of d,l-sotalol in patients with ventricular tachycardia (VT) or ventricular fibrillation (VF) and in survivors of cardiac arrest and to identify the factors that are associated with arrhythmia suppression and therefore might be helpful in predicting drug efficacy." | 3.69 | Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hief, C; Lammers, A; Martinez-Rubio, A; Mühlenkamp, S; Wichter, T, 1997) |
| " The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration." | 3.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| " At each dosing extreme, on-drug JTc was significantly longer in women (p < or =0." | 2.69 | JTc prolongation with d,l-sotalol in women versus men. ( Archibald, D; Hardy, S; Lehmann, MH; MacNeil, DJ, 1999) |
| "Its precise effect on the prevention of ventricular tachycardia-ventricular fibrillation (VTVF) compared to class I agents has not been evaluated in a blinded study." | 2.68 | Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. ( Kehoe, R; Quart, B; Scheinman, M; Singh, BN; Woosley, RL, 1995) |
| "The prevalence of arrhythmia in the population is increasing as more people survive for longer with cardiovascular disease." | 2.42 | A benefit-risk assessment of class III antiarrhythmic agents. ( Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C, 2004) |
| "Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers." | 2.40 | Sotalol: An important new antiarrhythmic. ( Anderson, JL; Prystowsky, EN, 1999) |
| "Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents." | 2.40 | Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. ( Hohnloser, SH, 1997) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | 2.40 | Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997) |
| " Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects." | 2.40 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. ( MacNeil, DJ, 1997) |
| "Torsade de pointes is a polymorphic ventricular tachyarrhythmia associated with a long QT interval." | 2.40 | Torsade de pointes with sotalol overdose treated successfully with lidocaine. ( Assimes, TL; Malcolm, I, 1998) |
| "For some arrhythmias, such as atrial fibrillation, it seems likely that drug therapy will remain an important part of treatment." | 2.39 | Is there a need for new antiarrhythmic drugs? ( Roden, DM, 1996) |
| " The objective of this study was to describe prescribing practices of sotalol and dofetilide and to compare safety outcomes between standard and nonstandard dosing strategies." | 1.56 | Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center. ( Knowles, D; Malloy, R; Ting, C, 2020) |
| "Sotalol is a bêta-blocker and class 3 anti-arrhythmic." | 1.51 | [Torsade de pointe resulting from a drug interaction between sotalol and ciprofloxacin]. ( Devaux, F; Fillet, M; Krzesinski, F, 2019) |
| "Antazoline is a first-generation antihistamine with antiarrhythmic properties." | 1.48 | Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. ( Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M, 2018) |
| "Ranolazine is a new agent which reduces pathologically elevated late INa but also IKr ." | 1.40 | Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model. ( Lüthje, L; Maier, LS; Seegers, J; Sohns, C; Sossalla, S; Toischer, K; Vollmann, D; Wallisch, N; Zabel, M, 2014) |
| "Heart failure was induced in 35 female rabbits by rapid ventricular pacing, resulting in a significant decrease of ejection fraction." | 1.37 | A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. ( Breithardt, G; Eckardt, L; Fehr, M; Frommeyer, G; Koopmann, M; Lücke, M; Milberg, P; Osada, N; Stypmann, J; Witte, P, 2011) |
| "Pheochromocytoma is an infrequent secondary cause of arterial hypertension, often associated with paroxysmal headache, sweating, weight loss, and palpitations." | 1.34 | Torsades de Pointes: a rare complication of an extra-adrenal pheochromocytoma. ( Beckmann, BM; Hinterseer, M; Kääb, S; Methe, H; Steinbeck, G; Wilbert-Lampen, U, 2007) |
| "Verapamil was used as an HERG channel blocker that is not associated with TdP." | 1.33 | Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. ( Andreas, JO; Hauser, R; Jahnel, U; Linz, K; Schneider, J, 2005) |
| "In amiodarone-treated, hypokalemic hearts, no EAD or TdP occurred." | 1.32 | Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. ( Breithardt, G; Eckardt, L; Haverkamp, W; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Wasmer, K, 2004) |
| " Preprinted order forms or procedural guidelines, as well as computer-assisted dosing programs, can be utilized to prevent inappropriate or miscalculated dosing of these agents, which potentially can cause life-threatening ventricular arrhythmias." | 1.32 | Initiation and monitoring of class III antiarrhythmic agents. ( Freeland, S; Worthy, C; Zolnierz, M, 2003) |
| "Better adherence to several dosing and monitoring recommendations in the dofetilide group may be caused by the presence of the risk-management program." | 1.32 | Evaluation of the dofetilide risk-management program. ( Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003) |
| "Prior to polymorphic ventricular tachycardia, dispersion of APD further increased (APD70max-min: 17 +/- 3 ms; APD90max-min: 25 +/- 3 ms; p < 0." | 1.32 | Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. ( Breithardt, G; Eckardt, L; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Milberg, P; Mönnig, G, 2003) |
| "Torsade de pointes is a rare but potentially fatal ventricular arrhythmia associated with drug-induced delayed repolarization and prolongation of the QT interval." | 1.31 | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. ( Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD, 2001) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| "In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1." | 1.31 | Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 1.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the arrhythmia during programmed stimulation." | 1.30 | Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. ( Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1997) |
| "Sotalol treatment was stopped and an infusion with lidocaine was started." | 1.30 | Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. ( Bergmann, P; Kallfelz, HC; Paul, T; Sasse, M, 1998) |
| "In the d,l-sotalol- and erythromycin-treated hearts, torsades de pointes occurred only in the presence of hypokalemia and bradycardia, whereas, in the presence of clofilium, bradycardia alone caused torsades de pointes." | 1.30 | Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin. ( Borggrefe, M; Breithardt, G; Clague, JR; Eckardt, L; Haverkamp, W; Johna, R; Mertens, H, 1998) |
| "d-Sotalol was used to mimic LQT2, whereas ATX-II mimicked LQT3." | 1.30 | Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. ( Antzelevitch, C; Shimizu, W, 1997) |
| "Sotalol has been commonly used in cases of angina pectoris and hypertension." | 1.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| "Sotalol dose was not appropriately adjusted for creatinine clearance which is age and gender dependent." | 1.29 | Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital. ( Basta, MN; Fletcher, PJ; Leitch, JW, 1996) |
| " Agents were compared over dosage ranges that produced maximal increases in QTc interval and monophasic action potential duration (MAPD)." | 1.29 | Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 49 (42.98) | 18.2507 |
| 2000's | 36 (31.58) | 29.6817 |
| 2010's | 23 (20.18) | 24.3611 |
| 2020's | 6 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Nogawa, H | 1 |
| Muraki, Y | 1 |
| Kawai, T | 1 |
| Kuninishi, Y | 1 |
| Savona, SJ | 1 |
| Daoud, EG | 1 |
| Lauterbach, M | 1 |
| Neuvonen, PJ | 1 |
| Elonen, E | 1 |
| Biswas, M | 1 |
| Levy, A | 1 |
| Weber, R | 1 |
| Tarakji, K | 1 |
| Chung, M | 1 |
| Noseworthy, PA | 2 |
| Newton-Cheh, C | 1 |
| Rosenberg, MA | 1 |
| Ting, C | 1 |
| Malloy, R | 1 |
| Knowles, D | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 1 |
| Sugiyama, A | 1 |
| Lee, S | 1 |
| Kittleson, MD | 1 |
| Chatterjee, D | 1 |
| Bhuiyan, TA | 1 |
| Graff, C | 2 |
| Kanters, JK | 2 |
| Melgaard, J | 1 |
| Toft, E | 2 |
| Kääb, S | 4 |
| Struijk, JJ | 2 |
| Ellermann, C | 1 |
| Sterneberg, M | 1 |
| Kochhäuser, S | 1 |
| Dechering, DG | 1 |
| Fehr, M | 2 |
| Eckardt, L | 8 |
| Frommeyer, G | 4 |
| Devaux, F | 1 |
| Fillet, M | 1 |
| Krzesinski, F | 1 |
| Park, J | 1 |
| Noh, K | 1 |
| Lee, HW | 1 |
| Lim, MS | 1 |
| Seong, SJ | 1 |
| Seo, JJ | 1 |
| Kim, EJ | 1 |
| Kang, W | 1 |
| Yoon, YR | 1 |
| Weeke, P | 1 |
| Delaney, J | 1 |
| Mosley, JD | 1 |
| Wells, Q | 2 |
| Van Driest, S | 1 |
| Norris, K | 1 |
| Kucera, G | 1 |
| Stubblefield, T | 1 |
| Roden, DM | 2 |
| Guérard, N | 1 |
| Jordaan, P | 1 |
| Dumotier, B | 1 |
| Sossalla, S | 1 |
| Wallisch, N | 1 |
| Toischer, K | 1 |
| Sohns, C | 1 |
| Vollmann, D | 1 |
| Seegers, J | 1 |
| Lüthje, L | 1 |
| Maier, LS | 1 |
| Zabel, M | 2 |
| Sugrue, A | 1 |
| Kremen, V | 1 |
| Qiang, B | 1 |
| Sheldon, SH | 1 |
| DeSimone, CV | 1 |
| Sapir, Y | 1 |
| Striemer, BL | 1 |
| Brady, P | 1 |
| Asirvatham, SJ | 1 |
| Ackerman, MJ | 1 |
| Friedman, P | 1 |
| Couderc, JP | 2 |
| Hinterseer, M | 3 |
| McNitt, S | 1 |
| Xia, X | 1 |
| Fossa, A | 1 |
| Beckmann, BM | 2 |
| Polonsky, S | 1 |
| Zareba, W | 2 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Quan, XQ | 1 |
| Bai, R | 2 |
| Lu, JG | 1 |
| Patel, C | 2 |
| Liu, N | 3 |
| Ruan, Y | 1 |
| Chen, BD | 1 |
| Ruan, L | 1 |
| Zhang, CT | 2 |
| Michiels, V | 1 |
| Miljoen, H | 1 |
| Vrints, C | 1 |
| Matz, J | 1 |
| Andersen, MP | 1 |
| Nielsen, J | 1 |
| Hardin, B | 1 |
| Raj, SR | 1 |
| Darbar, D | 1 |
| Jia, S | 1 |
| Lian, J | 1 |
| Guo, D | 1 |
| Xue, X | 1 |
| Yang, L | 1 |
| Yuan, Z | 1 |
| Ma, A | 1 |
| Yan, GX | 3 |
| Somberg, JC | 1 |
| Preston, RA | 1 |
| Ranade, V | 1 |
| Cvetanovic, I | 1 |
| Molnar, J | 1 |
| Wachowiak-Baszyńska, H | 1 |
| Straburzyńska-Migaj, E | 1 |
| Ochotny, R | 1 |
| Grajek, S | 1 |
| Milberg, P | 5 |
| Witte, P | 1 |
| Stypmann, J | 2 |
| Koopmann, M | 1 |
| Lücke, M | 1 |
| Osada, N | 4 |
| Breithardt, G | 9 |
| Uphaus, T | 1 |
| Kaiser, D | 1 |
| Pott, C | 1 |
| Fink, M | 1 |
| Ruhe, M | 1 |
| Matsuda, T | 1 |
| Baba, A | 1 |
| Klocke, R | 1 |
| Quang, TH | 1 |
| Nikol, S | 1 |
| Müller, FU | 1 |
| Noble, D | 1 |
| Isaza, C | 1 |
| Trombert, V | 1 |
| Chauveau, S | 1 |
| Derex, L | 1 |
| Chevalier, P | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 2 |
| Mönnig, G | 2 |
| Haverkamp, W | 6 |
| Wolbrette, DL | 1 |
| Tan, HH | 1 |
| Hsu, LF | 1 |
| Kam, RM | 1 |
| Chua, T | 1 |
| Teo, WS | 1 |
| Allen LaPointe, NM | 1 |
| Chen, A | 1 |
| Hammill, B | 1 |
| DeLong, E | 1 |
| Kramer, JM | 1 |
| Califf, RM | 1 |
| Spearritt, D | 1 |
| Freeland, S | 1 |
| Worthy, C | 1 |
| Zolnierz, M | 1 |
| Ruan, YF | 1 |
| Zhou, Q | 1 |
| Li, Y | 2 |
| Wang, L | 2 |
| Ramtin, S | 1 |
| Wasmer, K | 1 |
| Thomsen, MB | 1 |
| Verduyn, SC | 5 |
| Stengl, M | 1 |
| Beekman, JD | 1 |
| de Pater, G | 1 |
| van Opstal, J | 1 |
| Volders, PG | 1 |
| Vos, MA | 5 |
| Elming, H | 1 |
| Brendorp, B | 1 |
| Pehrson, S | 1 |
| Pedersen, OD | 1 |
| Køber, L | 1 |
| Torp-Petersen, C | 1 |
| Schneider, J | 1 |
| Hauser, R | 1 |
| Andreas, JO | 1 |
| Linz, K | 1 |
| Jahnel, U | 1 |
| Pu, J | 1 |
| D'Aloia, A | 1 |
| Faggiano, P | 1 |
| Brentana, L | 1 |
| Boldini, A | 1 |
| Pedrinazzi, C | 1 |
| Procopio, R | 1 |
| Dei Cas, L | 1 |
| Zimetbaum, PJ | 1 |
| Josephson, ME | 1 |
| Brunckhorst, CB | 1 |
| Yalta, K | 1 |
| Turgut, O | 1 |
| Yilmaz, A | 1 |
| Yilmaz, MB | 1 |
| Kendirlioglu, O | 1 |
| Karadas, F | 1 |
| Dubrey, SW | 1 |
| Grocott-Mason, R | 1 |
| Letsas, KP | 1 |
| Efremidis, M | 1 |
| Sideris, A | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Shah, SA | 1 |
| Kluger, J | 1 |
| White, CM | 1 |
| Fossa, AA | 1 |
| Wisialowski, T | 1 |
| Crimin, K | 1 |
| Wolfgang, E | 1 |
| Badilini, F | 1 |
| Sarapa, N | 1 |
| Methe, H | 1 |
| Wilbert-Lampen, U | 1 |
| Steinbeck, G | 1 |
| Aström-Lilja, C | 1 |
| Odeberg, JM | 1 |
| Ekman, E | 1 |
| Hägg, S | 1 |
| Sasse, M | 2 |
| Paul, T | 2 |
| Bergmann, P | 2 |
| Kallfelz, HC | 2 |
| Buchanan, LV | 1 |
| Kabell, G | 1 |
| Brunden, MN | 1 |
| Gibson, JK | 1 |
| Gorgels, AP | 2 |
| van der Zande, J | 3 |
| Leunissen, JD | 1 |
| Wellens, HJ | 4 |
| Chézalviel-Guilbert, F | 2 |
| Davy, JM | 2 |
| Poirier, JM | 3 |
| Weissenburger, J | 4 |
| Singh, BN | 1 |
| Kehoe, R | 1 |
| Woosley, RL | 2 |
| Scheinman, M | 1 |
| Quart, B | 2 |
| Lipcsei, GC | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Van de Loo, A | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 3 |
| Huynh-Do, U | 1 |
| Wahl, C | 1 |
| Sulzer, M | 1 |
| Bühler, H | 1 |
| Keusch, G | 1 |
| Appel, JM | 1 |
| Sigurd, B | 1 |
| Petersen, HH | 1 |
| Sandøe, E | 1 |
| Campbell, TJ | 1 |
| Basta, MN | 1 |
| Leitch, JW | 1 |
| Fletcher, PJ | 1 |
| Feroze, H | 1 |
| Suri, R | 1 |
| Silverman, DI | 1 |
| Hardy, S | 2 |
| Archibald, D | 2 |
| MacNeil, DJ | 4 |
| Dancey, D | 1 |
| Wulffhart, Z | 1 |
| McEwan, P | 1 |
| Kühlkamp, V | 1 |
| Mermi, J | 1 |
| Mewis, C | 1 |
| Seipel, L | 1 |
| van Uum, SH | 1 |
| van den Merkhof, LF | 1 |
| Lucassen, AM | 1 |
| Wuis, EW | 1 |
| Diemont, W | 1 |
| van der Hulst, FF | 1 |
| Martinez-Rubio, A | 1 |
| Hief, C | 1 |
| Lammers, A | 1 |
| Mühlenkamp, S | 1 |
| Wichter, T | 1 |
| Borggrefe, M | 3 |
| Link, MS | 1 |
| Foote, CB | 1 |
| Sloan, SB | 1 |
| Homoud, MK | 1 |
| Wang, PJ | 1 |
| Estes, NA | 1 |
| Krishnan, SC | 1 |
| Galvin, J | 1 |
| McGovern, B | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Shimizu, W | 2 |
| Antzelevitch, C | 6 |
| Doig, JC | 1 |
| Hohnloser, SH | 2 |
| Kulcsàr, A | 1 |
| Behrens, S | 1 |
| Li, YG | 1 |
| Hördt, M | 1 |
| Pratt, CM | 1 |
| Camm, AJ | 1 |
| Cooper, W | 1 |
| Friedman, PL | 1 |
| Moulton, KM | 1 |
| Pitt, B | 1 |
| Schwartz, PJ | 1 |
| Veltri, EP | 1 |
| Waldo, AL | 1 |
| Deplanne, V | 1 |
| Xia, YZ | 1 |
| Cheymol, G | 1 |
| Assimes, TL | 1 |
| Malcolm, I | 1 |
| Mertens, H | 1 |
| Johna, R | 1 |
| Clague, JR | 1 |
| Bathen, J | 1 |
| Madsen, S | 1 |
| Smith, W | 1 |
| Anderson, JL | 1 |
| Prystowsky, EN | 1 |
| Cammu, G | 1 |
| Geelen, P | 1 |
| Baetens, P | 1 |
| De Vos, J | 1 |
| Demeyer, I | 1 |
| Delacrétaz, E | 1 |
| Fuhrer, J | 1 |
| Lacroix, D | 1 |
| Extramiana, F | 1 |
| Delfaut, P | 1 |
| Adamantidis, M | 1 |
| Grandmougin, D | 1 |
| Klug, D | 1 |
| Kacet, S | 1 |
| Dupuis, B | 1 |
| Merot, J | 1 |
| Charpentier, F | 1 |
| Coutris, G | 1 |
| Nesterenko, VV | 1 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Marill, KA | 1 |
| Runge, T | 1 |
| Gintant, GA | 1 |
| Limberis, JT | 1 |
| McDermott, JS | 1 |
| Wegner, CD | 1 |
| Cox, BF | 1 |
| Farkas, A | 1 |
| Leprán, I | 1 |
| Papp, JG | 1 |
| Emori, T | 1 |
| Akar, FG | 1 |
| Rosenbaum, DS | 1 |
| Arstall, MA | 1 |
| Hii, JT | 1 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Sieber, C | 1 |
| Weiss, P | 1 |
| Follath, F | 1 |
| Singh, SN | 1 |
| Lazin, A | 1 |
| Cohen, A | 1 |
| Johnson, M | 1 |
| Fletcher, RD | 1 |
| Moak, JP | 1 |
| Liechti, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for sotalol and Torsade de Pointes
| Article | Year |
|---|---|
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Humans; Hy | 2003 |
Torsades de pointes following cardioversion: case history and literature review.
Topics: Aged; Anti-Arrhythmia Agents; Critical Care; Electric Countershock; Electrocardiography; Female; Hum | 2003 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modalit | 2004 |
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Electro | 2007 |
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
Is there a need for new antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Propafeno | 1996 |
Drug-induced cardiac arrhythmias: incidence, prevention and management.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents; | 1997 |
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Myocardia | 1997 |
The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Conduction System; Heart Failur | 1997 |
Torsade de pointes with sotalol overdose treated successfully with lidocaine.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Follo | 1998 |
Sotalol: An important new antiarrhythmic.
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibri | 1999 |
Meta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Infusions, Intravenous; | 2001 |
6 trials available for sotalol and Torsade de Pointes
| Article | Year |
|---|---|
Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Sotalol; Torsades de | 2009 |
Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.
Topics: Adolescent; Adult; Algorithms; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Aza Compounds; Cardiov | 2010 |
Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiac Pacing, Artificial; Double-Blind Method; Elec | 1995 |
Proarrhythmic complications of sotalol.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Hospitals, Teaching; Humans; Male; New South W | 1996 |
Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Age | 1998 |
JTc prolongation with d,l-sotalol in women versus men.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiomyopathies; Electrocardiography; Female; Humans; | 1999 |
96 other studies available for sotalol and Torsade de Pointes
| Article | Year |
|---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Pharmacological characterisation of electrocardiogram J-T
Topics: Animals; DNA-Binding Proteins; Electrocardiography; Flecainide; Guinea Pigs; Long QT Syndrome; Nifed | 2022 |
Something Old, Something New: Reinventing Antiarrhythmic Drug Loading With Intravenous Sotalol.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Sotalol; Torsades de Pointes | 2023 |
Response to Neuvonen et al: Sotalol, unlike the other beta-blockers, increases the QT
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Drug Overdose; Humans; Sotalol; Torsades | 2019 |
Sotalol, unlike the other beta-blockers, increases the QT
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Humans; Sotalol; Torsades de Pointes | 2019 |
Multicenter Analysis of Dosing Protocols for Sotalol Initiation.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Drug D | 2020 |
Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Topics: Academic Medical Centers; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Boston; Drug Dosage Cal | 2020 |
Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model.
Topics: Animals; Atrioventricular Block; Bepridil; Cisapride; Computer Simulation; Macaca fascicularis; Sota | 2021 |
Naturally occurring torsades de pointes and QT interval prolongation in a domestic cat.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cat Diseases; Cats; Electrocardiography; Long QT Syndro | 2021 |
A case of palpitation and pre-syncope.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Sotalol; Sy | 2017 |
A History of Drug-Induced Torsades de Pointes Is Associated With T-wave Morphological Abnormalities.
Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Sotalol; Torsa | 2018 |
Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Antazoline; Anti-Bacterial Agents; Arrhythm | 2018 |
[Torsade de pointe resulting from a drug interaction between sotalol and ciprofloxacin].
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Electrocardiography | 2019 |
Pharmacometabolomic approach to predict QT prolongation in guinea pigs.
Topics: Animals; Electrocardiography; Fluoroquinolones; Guinea Pigs; Male; Metabolic Networks and Pathways; | 2013 |
QT variability during initial exposure to sotalol: experience based on a large electronic medical record.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Electronic Health Records; Female; Heart | 2013 |
Analysis of unipolar electrograms in rabbit heart demonstrated the key role of ventricular apicobasal dispersion in arrhythmogenicity.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Cardiac; Chromans; Electrophysiologic Te | 2014 |
Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dose-R | 2014 |
Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.
Topics: Aged; Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Humans; Male; Middl | 2015 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Pharmacological enhancement of cardiac gap junction coupling prevents arrhythmias in canine LQT2 model.
Topics: Animals; Anti-Arrhythmia Agents; Connexin 43; Disease Models, Animal; Dogs; Drug Evaluation, Preclin | 2009 |
Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes.
Topics: Acute Kidney Injury; Aged, 80 and over; Anti-Arrhythmia Agents; Aortic Valve Insufficiency; Bumetani | 2009 |
Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.
Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Drug Interactions; Electrocardiography; Female; Huma | 2010 |
Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Clarithromycin; Cnidarian Venoms; Heart Ventricles; P | 2011 |
Gender differences in cardiac repolarization following intravenous sotalol administration.
Topics: Adult; Female; Humans; Infusions, Intravenous; Long QT Syndrome; Male; Sex Characteristics; Sotalol; | 2012 |
Late proarrhythmia on sotalol therapy triggered by emotional stress.
Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Sotalol; Stress, Psychological; T | 2011 |
A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Female; He | 2011 |
Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Electrocardiography; El | 2012 |
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart; Heart | 2012 |
[Practical ECG problems. Torsade de pointes in an elderly patient].
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Sotalol; Torsades de | 2012 |
A heartless brain.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Female; Humans; Long QT Syndrome; Sotalol; Stroke; Torsad | 2013 |
Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Elect | 2003 |
A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged; Sotalol; Torsades de | 2003 |
Evaluation of the dofetilide risk-management program.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Electroc | 2003 |
Initiation and monitoring of class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Drug Approval; Drug Label | 2003 |
Experimental study on the mechanism of sex difference in the risk of torsade de pointes.
Topics: Action Potentials; Animals; Electrocardiography; Female; Male; Rabbits; Risk; Sex Characteristics; S | 2004 |
Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Disease Models, Animal; Drug Administr | 2004 |
Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Cardiac Complexes, Premature; Chronic Disea | 2004 |
Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Topics: Animals; Calcium Channel Blockers; Dogs; Electrocardiography; Ether-A-Go-Go Potassium Channels; Huma | 2005 |
[Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model].
Topics: Animals; Calmodulin; Enzyme Inhibitors; Female; In Vitro Techniques; Rabbits; Sotalol; Sulfonamides; | 2005 |
Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged; Recu | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Sex Factors; Sotalol; | 2005 |
[Conversion to sinus rhythm].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Diagnosis, Differential; Diarrhea; Electri | 2006 |
Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
Topics: Adult; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Female; Humans; Long QT Syndrome; S | 2007 |
Drug-induced QT prolongation: consequences and current dilemma.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Bisoprolol; Electrocardiography; Female; Humans; Long QT | 2007 |
Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
Topics: Adult; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Ra | 2008 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |
Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Female; Humans; Long QT | 2007 |
Torsades de Pointes: a rare complication of an extra-adrenal pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Pheochr | 2007 |
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Ca | 2008 |
[Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant].
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Electrocardiography; Female; Humans; Infant; Sotalol; Torsade | 1995 |
Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiography; Heart Conduction System; Heart | 1993 |
The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels; Disease Models, Animal; Dogs; | 1995 |
Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Drug Inte | 1995 |
Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Chronic Disease; Disease Models, Animal; Dog | 1995 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients.
Topics: Adrenergic beta-Antagonists; Aged; Electrocardiography; Female; Heart Arrest; Humans; Male; Middle A | 1996 |
[Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels].
Topics: Aged; Anti-Arrhythmia Agents; Female; Humans; Sotalol; Torsades de Pointes | 1996 |
[Sotalol and torsades de pointes ventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Diagnosis, Differential; Female; Humans; | 1996 |
Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hospitals, Teac | 1996 |
Torsades de pointes from terfenadine and sotalol given in combination.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Electrocardiography; Female; H | 1996 |
Sex difference in risk of torsade de pointes with d,l-sotalol.
Topics: Adult; Aged; Aging; Anti-Arrhythmia Agents; Female; Heart Rate; Humans; Information Systems; Male; M | 1996 |
Sotalol-induced torsades de pointes in patients with renal failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Electrocardiography; F | 1997 |
Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle | 1997 |
Successful haemodialysis in sotalol-induced torsade de pointes in a patient with progressive renal failure.
Topics: Adrenergic beta-Antagonists; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Sotalol | 1997 |
Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Electrocardiog | 1997 |
Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Electric Stimulation; Female; Follow-Up Studies; Heart | 1997 |
Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis.
Topics: Adult; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Female; Humans; Long QT Syndrome; | 1997 |
Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electric Stimulation; Electrocardiography; Human | 1997 |
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benz(a)Anthracenes; Dogs; Electrocardiography; H | 1997 |
Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own co
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Dogs; Electrocardiography; Female; Male; Prop | 1997 |
Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Disease Models, Anima | 1997 |
Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia--evidence for a significant contribution of the "cardiac memory".
Topics: Administration, Oral; Anti-Arrhythmia Agents; Catheter Ablation; Electric Countershock; Electrocardi | 1998 |
Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Electrocardiography; Female; Humans; Infant; Sotalol; Torsade | 1998 |
Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Drug Therapy, C | 1998 |
Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
Topics: Animals; Bradycardia; Electrocardiography; Erythromycin; Hypokalemia; In Vitro Techniques; Male; Qua | 1998 |
Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Electrocardiography; Endo | 1998 |
[Sotalol--atrial fibrillation, reduced renal function and sudden death].
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Death, Sudden, Cardiac; | 1998 |
A case of sotalol associated torsades de pointes tachycardia in a 15 month old child.
Topics: Anti-Arrhythmia Agents; Humans; Infant; Sotalol; Torsades de Pointes | 1999 |
Two cases of torsades de pointes caused by sotalol therapy.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Sotalol; Torsa | 1999 |
Fatal torsade de pointes with d,l-sotalol and low potassium.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Electrocardiography; Fatal Outcome; Female; H | 1999 |
Factors affecting epicardial dispersion of repolarization: a mapping study in the isolated porcine heart.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Electrophysiology; Female; Image Pr | 1999 |
Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
Topics: Action Potentials; Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Cardiac Pacing | 1999 |
Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia.
Topics: Action Potentials; Anesthesia, General; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Di | 2000 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Chromans; Cnidarian Venoms; | 2000 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; D | 2001 |
Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Electrocardiography; El | 2002 |
Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Amiodarone; Animals; Anti-Arrhythmi | 2002 |
Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Dogs; Electrocar | 2001 |
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome.
Topics: Action Potentials; Animals; Body Surface Potential Mapping; Disease Models, Animal; Dogs; Electric S | 2002 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
[Hemiparesis and torsade de pointes under low-dose sotalol therapy].
Topics: Aged; Aged, 80 and over; Cardiac Complexes, Premature; Electrocardiography; Epilepsy; Female; Hemipl | 1990 |
Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy.
Topics: Aged; Electrocardiography; Humans; Male; Renal Dialysis; Sotalol; Torsades de Pointes | 1991 |
Developmental cellular electrophysiologic effects of d-sotalol on canine cardiac Purkinje fibers.
Topics: Action Potentials; Animals; Animals, Newborn; Dogs; Electrophysiology; In Vitro Techniques; Potassiu | 1991 |
[Concerning "Hemiparesis and torsades de pointes with low dosage sotalol therapy" by C. Sieber, Ph. Weiss and F. Follath (Schweiz. med. Wschr. 1990; 120: 1397-1399)].
Topics: Aged; Drug Interactions; Female; Hemiplegia; Humans; Maprotiline; Sotalol; Torsades de Pointes | 1991 |